Preventing the papillomavirus infectious and herpes zoster: New vaccines;Prévention des infections à papillomavirus et du zona: Nouveaux vaccins

Medecine/Sciences

Volumn 23, Issue 4, 2007, Pages 423-427

  Silbermann, Benjamin ^a   Launay, Odile ^a  

^a Hôpital Cochin ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B VACCINE; VARICELLA ZOSTER VACCINE; VIRUS PROTEIN; WART VIRUS VACCINE;

CANCER PREVENTION; DRUG SAFETY; GENOTYPE; HERPES ZOSTER; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; POSTHERPETIC NEURALGIA; PROPHYLAXIS; REVIEW; SEXUALLY TRANSMITTED DISEASE; UTERINE CERVIX CANCER; VERRUCA VULGARIS; VIRUS LIKE AGENT;

HERPES ZOSTER; HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; PAPILLOMAVIRIDAE;

EID: 34247258297     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/2007234423     Document Type: Review

References (43)

1. Lowy OR, Howley PH, Papillomaviruses. In : Knipe DM, Howley PH, eds. Fields virology. Philadelphia, Pennsylvania, USA : Lippincott, Williams and Wilkms, 2001 : 2231-64.
2. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003 ; 348 : 518-27.
3. Munoz N, Bosch FX, Castellsague X, et al. Against which human papillomavirus types shall we vaccinate and screen ? The international perspective. Int J Cancer 2004 ; 111 : 278-85.
4. Peto J, Gilham C, Deacon J, et al. Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort. Br J Cancer 2004 ; 91 : 942-53.
5. Vang BH, Bray FI, Parkin DM, et al. Cervical cancer as a priority for prevention in different world regions: an evaluation using years of life lost. Int J Cancer 2004 ; 109 : 418-24.
6. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999 ; 189 : 12-9.
7. Zhou J, Sun XY, Stenzel DJ, Frazer IH. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 1991 ; 185 : 251-7.
8. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women : a randomised controlled trial. Lancet 2004 ; 364 : 1757-65.
9. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002 ; 347 : 1645-51.
10. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005 ; 6 : 271-8.
11. Mao C, Koutsky LA, Ault KA, et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 2006 ; 107 : 18-27.
12. Rose RC, Reichman RC, Bonnez W. Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera. J Gen Virol 1994 ; 75 : 2075-9.
13. Roden RB, Hubbert NL, Kirnbauer R, et al. Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition. J Virol 1996 ; 70 : 3298-301.
14. Koutsky LA, Harper DM. Current findings from prophylactic HPV vaccine trials. Vaccine 2006 ; 24 (suppl 3) : S114-21.
15. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18 : follow-up from a randomised control trial. Lancet 2006 ; 367 : 1247-55.
16. Villa LL, Costa RL, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006 ; 95 : 1459-66.
17. Block SL, Nolan T, Sattler C, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006 ; 118 : 2135-45.
18. Villa LL, Ault KA, Giuliano AR, et al. Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18. Vaccine 2006 ; 24 : 5571-83.
19. Poland GA, Jacobson RM, Koutsky LA, et al. Immunogenicity and reactogenicity of a novel vaccine for human papillomavirus 16 : a 2-year randomized controlled clinical trial. Mayo Clin Proc 2005 ; 80 : 601-10.
20. Grunbaum JA, Kann L, Kinchen S, et al. Youth risk behavior surveillance: United States, 2003. MMWR Surveill Summ 2004 ; 53 : 1-96.
21. Winer RL, Lee SK, Hughes JP, et al. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003 ; 157 : 218-26.
22. Hughes JP, Garnett GP, Koutsky L. The theoretical population-level impact of a prophylactic human papilloma virus vaccine. Epidemiology 2002 ; 13 : 631-9.
23. Hawes SE, Critchlow CW, Faye Niang MA, et al. Increased risk of high-grade cervical squamous intraepithelial lesions and invasive cervical cancer among African women with human immunodeficiency virus type 1 and 2 infections. J Infect Dis 2003 ; 188 : 555-63.
24. Weller TH. Serial propagation in vitro of agents producing inclusion bodies derived from varicella and herpes zoster. Proc Soc Exp Biol Med 1953 ; 83 : 340-6.
25. Preblud SR, Orenstein WA, Bart Kj. Varicella: clinical manifestations, epidemiology, and health impact in children. Pediatr Infect Dis 1984 ; 3 : 505-9.
26. Leclair JM, Zaia JM, Levin MJ, et al. Airborne transmission ofchickenpox in a hospital. N Engl J Med 1980 ; 302 : 450-3.
27. Hope-Simpson RE. The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Med 1965 ; 58 : 9-20.
28. Gershon A, Steinberg S, Borkowsky W, et al. Subclinical zoster: identification by serum IgM to varicella-zoster virus. Pediatr Res 1981 ; 15 : 610.
29. Gnann JW Jr, Whitley RJ. Clinical practice. Herpes zoster. N Engl J Med 2002 ; 347 : 340-6.
30. Oxman MN. Clinical manifestations of herpes zoster. In : Arvin AM, Gershon AA, eds. Varicella zoster virus : virology and clinical management. Cambridge, England : Cambridge University Press, 2000 : 246-75.
31. Ragozzino MW, Melton LJ, Kurland LT, et al. Population-based study of herpes zoster and its sequelae. Medicine 1982 ; 61 : 310-6.
32. Jung BF, Johnson RW, Griffin DR, Dworkin RH. Risk factors for postherpetic neuralgia in patients with herpes zoster. Neurology 2004 ; 62 : 1545-51.
33. D workin RH, Schmader KE. The treatment and prevention of postherpetic neuralgia. Clin Infect Dis 2003 ; 36 : 877-82.
34. Kost RG, Straus SE. Postherpetic neuralgia: pathogenesis, treatment, and prevention. N Engl J Med 1996 ; 335 : 32-42.
35. Buchbinder SP, Katz MH, Hessol NA, et al. Herpes zoster and human immunodeficiency virus infection. J Infect Dis 1992 ; 166 : 1153-6.
36. Weller TH. Varicella and herpes zoster : changing concepts of the natural history, control and importance of a not-so-benign virus (part two). N Engl J Med 1983 ; 309 : 1434-40.
37. Glesby MJ, Moore RD, Chaisson RE. Clinical spectrum of herpes zoster in adults infected with human immunodeficiency virus. Clin Infect Dis 1995 ; 21 : 370-5.
38. Takahashi M, Otsuka T, Okuno Y, et al. Live vaccine used to prevent the spread of varicella in children in hospital. Lancet 1974 ; 2 : 1288-90.
39. Hambleton S, Gershon AA. Preventing varicella-zoster disease. Clin Microbiol Rev 2005 ; 18 : 70-80.
40. Sharrar RG, LaRussa P, Galea S, et al. The postmarketing safety profile of varicella. Vaccine 2001 ; 19 : 916-23.
41. Vazquez M, LaRussa P, Gershon A, et al. The effectiveness of the varicella vaccine in clinical practice. N Engl J Med 2001 ; 344 : 955-60.
42. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005 ; 352 : 2271-84.
43. Tyring SK, Diaz-Mitoma F, Padget LG, et al. Safety and tolerability of a high-potency zoster vaccine in adults ≥50 years of age. Vaccine 2007 ; 25 : 1877-83.